AtriCure (Nasdaq:ATRC) announced today that it treated the first patient in its HEAL-IST clinical trial in Belgium. Dr. Mark LaMeir and Dr. Carlo de Asmundis treated the first patient in the HEAL-IST trial evaluating the AtriCure Isolator Synergy clamp for treating drug-refractory patients diagnosed with inappropriate sinus tachycardia (IST) at University Hospital Brussels. “Symptomatic IST […]
atricure
AtriCure beats The Street in Q1 results
AtriCure (Nasdaq:ATRC) this week posted first-quarter results that beat the overall consensus on Wall Street. The Mason, Ohio-based cardiac ablation device company reported losses of $15.2 million, or -34¢ per share, on sales of $74.6 million for three months ended March 31, for a bottom-line gain of 10.3% on sales growth of 25.8% compared with […]
AtriCure launches clamp for cardiac tissue ablation
AtriCure (Nasdaq:ATRC) announced today that it launched the EnCompass Clamp as part of its Isolator Synergy ablation system. Mason, Ohio-based AtriCure received FDA 510(k) clearance for the EnCompass Clamp for the ablation of cardiac tissue during cardiac surgery to make concomitant surgical ablations more efficient. According to a news release, the platform includes parallel closure, […]
These 10 medtech companies’ stocks performed best in 2021
Following a year like no other in 2020, 2021 was when many looked to rebound — including the medtech industry. A number of medtech companies followed up a challenging, pandemic-enveloped year with impressive performances. Plenty of them had already proven in 2020 that they were capable of a quick bounce-back. Here are 10 medtech companies […]
AtriCure publishes first environmental, social, governance report
AtriCure (NASDAQ:ATRC) this month released its first environmental, social and governance (ESG) report that highlights the company’s corporate responsibility and sustainability initiatives. Companies produce corporate responsibility for corporate stakeholders who are interested in ESG-related information. AtriCure’s ESG report includes data metrics such as the gender diversity of its management and workforce and the racial diversity […]
AtriCure posts Street-beating Q3 results, maintains full-year outlook
AtriCure (NSDQ:ATRC) posted third-quarter results today that beat the consensus forecast on Wall Street and maintained its outlook for the full year. The Mason, Ohio-based atrial fibrillation (AFib) technology developer reported profits of $97.1 million, or $2.11 per diluted share, on sales of $70.5 million for the three months ended Sept. 30. Sales grew 28.7% […]
DTW Podcast: How AtriCure built a big business in Afib; A deep look into Abbott’s new Coronary imaging platform
In this week’s episode of the DeviceTalks Weekly Podcast, Dr. Nick West, CMO & divisional VP of global medical affairs at Abbott’s vascular business, discusses the European launch of the company’s new coronary imaging platform. Dr. West explains how the AI-powered platform works and the benefits it offers for decision-making during coronary stenting procedures. He […]
5 of the latest cardiac tech insights out of ACC.21
The American College of Cardiology’s 70th Annual Scientific Session has produced some positive news about some controversial cardiac tech. Drug-coated stents, which a 2018 study linked to late-stage death, were shown to be non-inferior to non-drug-coated stents in patients with peripheral arterial disease. And a new study of renal denervation that used a different methodology […]
AtriCure AFib treatment device wins FDA approval
AtriCure (NSDQ:ATRC) announced today that the FDA approved its EPi-Sense system for treating long-standing persistent atrial fibrillation (Afib). Mason, Ohio-based AtriCure’s EPi-Sense system demonstrated superiority in the Hybrid AF therapy arm compared to endocardial catheter ablation alone in the Converge clinical trial, according to a news release. AtriCure’s Hybrid AF therapy is a minimally invasive […]
AtriCure beats the Street in Q1 results
AtriCure (NASDAQ:ATRC) posted first-quarter results today that beat the consensus forecast on Wall Street. The Mason, Ohio-based company reported losses of -$16.9 million, or -38¢ per share, on sales of $59.3 million for the three months ended March 31, for a sales growth of 11.37% compared with Q1 2020. Adjusted to exclude one-time items, earnings per […]
